These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22285805)

  • 21. Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation.
    Van Wagner LB; Baker T; Ahya SN; Norvell JP; Wang E; Levitsky J
    J Hepatol; 2009 Nov; 51(5):874-80. PubMed ID: 19643508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation.
    Kontorinis N; Agarwal K; Elhajj N; Fiel MI; Schiano TD
    Liver Transpl; 2006 May; 12(5):827-30. PubMed ID: 16628699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cryptosporidiosis in a patient on PEG-interferon and ribavirin for recurrent hepatitis C after living donor liver transplantation.
    Manz M; Steuerwald M
    Transpl Infect Dis; 2007 Mar; 9(1):60-1. PubMed ID: 17313476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.
    Stanca CM; Fiel MI; Kontorinis N; Agarwal K; Emre S; Schiano TD
    Transplantation; 2007 Jul; 84(2):180-6. PubMed ID: 17667809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha.
    Hassan Q; Roche B; Buffet C; Bessede T; Samuel D; Charpentier B; Durrbach A
    Transpl Int; 2012 Sep; 25(9):941-7. PubMed ID: 22882335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
    Berardi S; Lodato F; Gramenzi A; D'Errico A; Lenzi M; Bontadini A; Morelli MC; Tamè MR; Piscaglia F; Biselli M; Sama C; Mazzella G; Pinna AD; Grazi G; Bernardi M; Andreone P
    Gut; 2007 Feb; 56(2):237-42. PubMed ID: 16798778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].
    Huang YX; Chen XY; Ma LN; Yin JM; Ren S; Guo DD; Zheng YH
    Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):216-20. PubMed ID: 22475143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience.
    Jain A; Sharma R; Ryan C; Safadjou S; Kashyap R; Mantry P; Maliakkal B; Orloff M
    Clin Transplant; 2010; 24(1):104-11. PubMed ID: 19239480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current management and perspectives for HCV recurrence after liver transplantation.
    Coilly A; Roche B; Samuel D
    Liver Int; 2013 Feb; 33 Suppl 1():56-62. PubMed ID: 23286847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
    Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T
    Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin.
    Bizollon T; Ducerf C; Trépo C
    J Hepatol; 1995; 23 Suppl 2():22-5. PubMed ID: 8720290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.
    Angelico M; Petrolati A; Lionetti R; Lenci I; Burra P; Donato MF; Merli M; Strazzabosco M; Tisone G
    J Hepatol; 2007 Jun; 46(6):1009-17. PubMed ID: 17328985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
    Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
    Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C.
    Liu CH; Liang CC; Liu CJ; Lin JW; Chen SI; Hung PH; Tsai HB; Lai MY; Chen PJ; Chen DS; Kao JH
    Clin Infect Dis; 2010 Sep; 51(5):541-9. PubMed ID: 20645865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of hepatic granulomas in patients receiving pegylated interferon therapy for recurrent hepatitis C virus post liver transplantation.
    Fiel MI; Shukla D; Saraf N; Xu R; Schiano TD
    Transpl Infect Dis; 2008 Jun; 10(3):184-9. PubMed ID: 17916116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.
    Bizollon T; Palazzo U; Ducerf C; Chevallier M; Elliott M; Baulieux J; Pouyet M; Trepo C
    Hepatology; 1997 Aug; 26(2):500-4. PubMed ID: 9252166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
    Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H
    Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients.
    Castells L; Esteban JI; Bilbao I; Vargas V; Allende H; Ribera E; Piron M; Sauleda S; Len O; Pahissa A; Esteban R; Guardia J; Margarit C
    Antivir Ther; 2006; 11(8):1061-70. PubMed ID: 17302376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.